Stockscreener 앱 받기
25.65
1.84%
-0.48
전일 마감가:
$26.13
열려 있는:
$25.98
하루 거래량:
1.97M
Relative Volume:
0.48
시가총액:
$3.29B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-27.58
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
-11.40%
1개월 성능:
-10.53%
6개월 성능:
-58.38%
1년 성능:
-68.72%
1일 변동 폭
$25.21
$26.23
1주일 범위
$25.21
$29.60
52주 변동 폭
$24.44
$82.00
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
25.65 | 3.29B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
A Closer Look at Viking Therapeutics's Options Market Dynamics - Benzinga
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study - Investor's Business Daily
Health Care Down as Viking Slides -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet - Patient Care Online
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Marketscreener.com
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - StockTitan
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - MSN
(VKTX) Investment Analysis - Stock Traders Daily
Market Whales and Their Recent Bets on VKTX Options - Benzinga
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Yahoo
Why Novo Nordisk Stock Outpaced the Market on Tuesday - The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat
Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN
Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN
Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha
(VKTX) Long Term Investment Analysis - Stock Traders Daily
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research
Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World
10 Stocks Skyrocketing Today - Insider Monkey
Why VKTX Stock is Moving Today - GuruFocus.com
Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo
Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking shares slip after manufacturing deal announced - The Pharma Letter
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance
Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks
Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks
Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - Barchart
Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha
Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance
Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance
Viking Therapeutics Shares Fall After Manufacturing Deal With CordenPharma -March 11, 2025 at 11:08 am EDT - Marketscreener.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook - TipRanks
Viking Therapeutics Signs Broad Manufacturing Agreement with CordenPharma - Contract Pharma
Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications - Marketscreener.com
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mancini Marianna | Chief Operating Officer |
Jan 06 '25 |
Sale |
42.75 |
54,215 |
2,317,599 |
374,134 |
| ZANTE GREG | Chief Financial Officer |
Jan 06 '25 |
Sale |
42.75 |
50,309 |
2,150,595 |
165,259 |
0.39%
0.34%
자본화:
|
볼륨(24시간):